Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
NEWTON, Mass., March 29, 2017 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference in New York on Wednesday, April 5, 2017 at 3:00 p.m. ET.
A live webcast of the event can be accessed under "Events & Presentations" in the Investors section of the Company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,900 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
Contacts: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
